Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours Β· Estimated delivery Aug 7 - Aug 12
Injectable GHK-Cu is not FDA-approved
Studies show FOXO4-DRI treatment reduces senescent cell burden by 50-70% in various tissues including liver, kidney, and adipose tissue within weeks of treatment initiation in aged mice
Pharmaceutical Companies: These entities are investing in GHK-Cu due to its potential therapeutic use in anti-inflammatory therapies, tissue regeneration, and systemic applications
BorderFreeHealth offers U.S.-from-Canada service for customers who need cash-pay prescription access, with order details reviewed when required for safe supply through licensed pharmacies
Learn what to watch for and when to contact your provider
International Journal of Cosmetic Science 27(3):155-160. [doi.org]
US$ 22.09
US$ 24.40
US$ 22.75
US$ 29.29
